Immunocore to present at the Jefferies London Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place November 16-19, 2021.
The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. The webcast can also be accessed in the ‘Investors’ section of Immunocore’s website at www.immunocore.com.